Compare PubMatic Inc (PUBM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs ResMed Inc. — how do they compare? PubMatic Inc trades at $18.72 (market cap $850.88M), while ResMed Inc. trades at $231 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 37.5× PubMatic Inc's market cap, and ResMed Inc. pays a 1.16% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| PUBM | RMD | |
|---|---|---|
Market Cap | $850.88M | $31.89B |
Volume | 997,698 | 618,314 |
Sector | Technology | Health |
52-Week High | $19.18 | $277.88 |
52-Week Low | $6.28 | $182.82 |
Typical Hold Time | 40 Days | — |
Enterprise Value | $754.01M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.72, up 0.81% with bullish technical signals from moving averages. The company shows mixed fundamentals with strong revenue growth but negative profitability metrics, including a -4.66% net margin. Recent Q2 2026 earnings beat expectations with -$0.03 EPS versus -$0.18 expected, while analyst consensus remains strongly positive with 11 buy ratings and a $19.89 price target. Operating cash flow improved to $81M in 2025, supporting business stability.
The outlook suggests potential upside near analyst targets, though profitability challenges and CFO transition pose risks. Revenue growth in mobile app and CTV segments provides catalysts, while high P/E of 132 indicates premium valuation. Investment opportunity exists for growth-focused investors tolerant of current losses, with sentiment supported by AI-driven ad tech adoption.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
